Butyrate inhibits interleukin-17 and generates Tregs to ameliorate colorectal colitis in rats

Mingming Zhang¹,², Qian Zhou³, Robert G. Dorfman⁵, Xiaoli Huang⁶, Tingting Fan⁴, Hao Zhang⁷, Jun Zhang²* and Chenggong Yu¹*

Abstract

Background: Butyrate is an energy source for colonocytes that is formed by bacterial fermentation of dietary fiber in the colon and that exerts broad anti-inflammatory activities. Although the administration of butyrate improves homeostasis in patients and ameliorates IBD (Inflammatory Bowel Disease)-related lesions and symptoms, the anti-inflammatory mechanisms of butyrate still remain unclear. To explore the impact of butyrate on Treg (Regulatory T cell)/Th17 (T helper 17 cell) differentiation and colitis in rats.

Methods: The effect of butyrate on the expression of markers related to both Tregs and Th17 cells were determined in human monocytes as well as a rat model of colitis induced by 2,4,6-trinitrobenzene sulfonic acid. Rats were treated with butyrate in vivo, whereas the rat splenocytes and human monocytes were treated in vitro.

Results: We found that butyrate administration increased peripheral blood Treg cell levels as well as plasma levels of anti-Th17 cytokines (IL-10 and IL-12). Butyrate administration further suppressed IL-17 levels in both plasma and colonic mucosa, and ameliorated colonic colitis lesions in rats. This promotion of Treg activity and inhibition of IL-17 release was also observed in human venous monocytes and rat splenocytes in vitro.

Conclusions: Our results suggest that butyrate plays a key role in regulating the Treg/Th17 balance and ultimately protects the colon mucosa against the development of IBD.

Keywords: Butyrate, Inflammatory bowel disease, Cytokines, Th17, Treg

Background

Inflammatory bowel disease (IBD) consists of a group of disorders characterized by recurrent inflammation in the gastrointestinal tract. The two most common forms of IBD are ulcerative colitis (UC) and Crohn’s disease (CD). While the etiology of IBD remains uncertain, it has been hypothesized that an undesired intestinal mucosal immune response to luminal contents contributes to the onset of IBD in a genetically predisposed patient [1].

CD4⁺ T helper (Th) cells regulate immunity and inflammation through antigen-dependent activation and cytokine-dependent differentiation into functional T cell subsets. T helper 17 (Th17) cells are unique pro-inflammatory Th cells identified by retinoic acid receptor-related orphan receptor gamma t (RORyt) and interleukin-17 (IL-17) [2]. The IL-23/Th17/IL-17 pathway plays an important role in regulating IBD, and studies have found that Th17 levels are increased in both the colonic mucosa and serum of IBD patients [3]. Other T cells that differentiate from Th cells include regulatory T cells (CD4⁺CD25⁺FoxP3⁺ Treg), which play a key role in modulating the immune response [4]. Tregs are defined by the expression of both surface CD4⁺CD25⁺ and the intracellular transcription factor, FoxP3, which plays a key role in regulating Treg activity [5]. Tregs regulate the homeostasis of the intestinal immune system by promoting anti-inflammatory cytokine production, including interleukin-10 (IL-10), and exerting dominant negative

* Correspondence: archsteed@163.com; chenggong-yu@nju.edu.cn
²Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, China
³Department of Gastroenterology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing, China
Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
regulation of other T helper cells such as Th17 [6]. Tregs both produce and respond to TGF-β, an anti-inflammatory cytokine that plays an important role in maintaining Treg activity [7]. IL-6, an important signaling protein for maintaining the Treg/Th17 balance, suppresses Treg maturation and promotes a predominantly Th17 mediated pro-inflammatory response [8].

Short-chain fatty acids (SCFAs) are formed by bacterial fermentation of non-starch polysaccharides (NSP), such as dietary fiber in the colon [9]. Butyrate is mostly produced by Faecalibacterium prausnitzii (F. prausnitzii) and serves as an energy source for colonocytes. It appears to exert a promising anti-inflammatory effect by influencing immune cell migration, cytokine expression, and other cellular processes (eg. proliferation, activation and apoptosis) [10]. Studies in UC patients have suggested that both the administration of butyrate and the stimulation of luminal butyrate production by the ingestion of dietary fiber have an ameliorating effect on intestinal inflammation and related symptomology [11].

Although the administration of butyrate improves IBD-related lesions and symptoms, the exact anti-inflammatory mechanism remains unclear, and its impact on Treg/Th17 differentiation has not yet been examined. Therefore, the hypothesis of this study is that the administration of butyrate can ameliorate lesions and symptoms of colorectal UC in rats by inhibiting Th17 generation and promoting Tregs.

Table 1 Characteristics of the study population

| Characteristics | Control (N = 10) | UC (N = 7) | p Value |
|-----------------|-----------------|-----------|---------|
| Male/female (%) | 5/5(50/50)      | 3/4(43/57) | > 0.05  |
| Median (IQR) age (years) | 47(31–50.5) | 47(31–50.5) | > 0.05  |
| Median (IQR) duration of disease (years) | NA | 5(2–6.5) | NA |
| Median (IQR) BMI | 25(23–26.5) | 26(21–27) | > 0.05  |
| Medication | NA | NA | |
| S-Aminosalicylic acid (%) | 7(100) | NA | |
| Azathioprine (%) | 4(57) | NA | |
| Corticosteroids (%) | 2(29) | NA | |
| Anti-TNF (%) | 1(19) | NA | |
| Disease activity | NA | NA | |
| Remission (SCCAI Score < 5) | 3(43) | NA | |
| Active (SCCAI Score ≥ 5) | 4(57) | NA | |

Groups were compared by non-parametric analyses. BMI: body mass index, NA: not applicable. p < 0.05 was considered significant.

Short-chain fatty acids (SCFAs) assay

Fresh faecal samples were collected and stored at −80 °C. Faecal samples were mixed with water and centrifuged. The supernatant was filtered and mixed with ether and sulfuric acid. After high speed centrifugation, the ether layer was collected and measured in the Agilent 6890 N Gas Chromatograph Machine for SCFA concentrations.

Immunohistochemistry

Colon specimens were fixed in 4% formalin and embedded in paraffin. The sections were then incubated with rabbit anti-rat IL17 antibodies (Abcam) and then treated with immunoperoxidase using the DAB kit (Zsbio). Sections were scored in a blind manner using a protocol modified from Brown & Wahl [15].

Peripheral blood mononuclear cell (PBMC) culture

PBMCs were isolated from the venous blood of healthy donors [16]. The cells were subsequently suspended in complete medium (2 × 10⁶ cells/ml) and seeded in 24-well plates (2 × 10⁶ cells/well). PBMCs were then treated with PBS and different concentrations of sodium butyrate (Sigma), respectively, for 72 h in 24-well plates pre-coated with UV-irradiated E. coli at a PBMC:bacteria ratio of 1:10. After 72 h, the culture supernatant from the PBMCs was collected and stored.
at −80 °C for cytokine analysis. PBMCs were used for flow cytometry.

**FCM (flow cytometry) analysis of Treg cells**
Mononuclear cells were isolated from blood using Ficoll-Isopaue density gradient centrifugation (Ficoll-Paque, MP Biomedicals). FCM followed routine procedures, and cells were labeled with FITC anti-CD4 (eBioscience), APC anti-CD25 (eBioscience) and PE anti-Foxp3 (eBioscience).

**Primary splenocyte culture**
Untreated 7-week-old SD rats were sacrificed using cervical dislocation following ether exposure. The splenocytes were incubated with recombinant human TGF-β (2 ng/ml, Peprotech) and recombinant rat IL-6 (20 ng/ml, Peprotech) at 37 °C for 72 h, whereas the control was treated with vehicle. Experimental group cells were treated with PBS or different concentrations of sodium butyrate (Sigma) in addition to TGF-β and IL-6 [17].

**Primary splenocyte and bone marrow-derived dendritic cell (BMDC) culture**
Untreated 7-week-old SD rats were sacrificed using cervical dislocation following ether exposure. The splenocytes were incubated with recombinant human TGF-β (2 ng/ml, Peprotech) and recombinant rat IL-6 (20 ng/ml, Peprotech) at 37 °C for 72 h [17]. Immature BMDCs were isolated using a protocol modified from Inaba et al. [18], in the presence of recombinant rat IL-4 (10 ng/ml, Peprotech) and recombinant rat granulocyte-macrophage colony-stimulating factor (GM-CSF, 10 ng/ml, Peprotech).

**ELISA assay and western blotting**
Cytokines (IL-10, IL-17A, IL-12 p70, TGF-β1, IL-6 and IL-23) were measured using a commercially available ELISA kit (Bender: IL-10, IL-17A, IL-12 p70 kits; SABC: IL-23 kit; eBioscience: TGF-β1, IL-6 kits) according to the manufacturer's instructions. For western blotting, cells were lysed using 0.5 % NP40 lysis buffer and proteins were blotted following standard protocol. Antibodies to RORγt (Abcam) and actin (GenScript Corp) were purchased commercially.

**Statistics**
Data was expressed as the mean ± standard error of the mean (SE). The data was analyzed with one-way ANOVA followed by a post hoc Duncan test (SPSS 17.0). P < 0.05 was considered significant.

**Results**

**Intestinal fatty acid levels**
Ulcerative colitis patients had a net concentration of butyric acid that was significantly lower than that of healthy controls (Fig. 1a). Moreover, rats in the TNBS-treated colitis group had significantly lower net concentrations of butyric acid and total SCFA concentrations than did rats in the control group (Fig. 1b-c). Following administration of sodium butyrate, fecal concentration of butyric acid, total SCFA, and the percentage of butyric acid were higher in the butyrate group than in the colitis group (Fig. 1b-c).

**Body weight, colon histology and blood cytokine production**
Rats in the TNBS-treated colitis group had significantly smaller weight gain, as well as more severe inflammation and higher colon Neurath scores than did rats in the control group (Fig. 2a-c). Butyrate administration significantly ameliorated the weight loss, increased colon inflammation, and higher Neurath scores observed in rats within the colitis group (Fig. 2a-c). Butyrate-treated rats only displayed mild mucosal and/or submucosal inflammation with a relatively low level of neutrophil infiltration.
and mild edema (Fig. 2b). Plasma cytokines, such as IL-12, IL-10 and the IL-10/IL-12 ratio, can be used to assess systemic levels of inflammation [19]. Plasma levels of IL-10 and the IL-10/IL-12 ratio were higher in the butyrate group than in the colitis group (Fig. 2d and f), but IL-12 levels were lower. The colonic cytokine results were consistent with the plasma results.

Treg analysis in rats

In vivo studies demonstrated a significantly lower percentage of CD25 + Foxp3+ Tregs in the peripheral blood of rats from the TNBS-treated colitis group than in the control group (Fig. 3a and b). Following treatment with butyrate, the percentage of CD25 + Foxp3+ Tregs in the peripheral blood increased (Fig. 3a and b). With sufficient IL-6, TGF-β can stimulate native T cells to differentiate into Th17 cells [2]. However, without sufficient IL-6, TGF-β stimulates native T cell differentiation into Tregs [20]. As CD25 + Foxp3+ Treg frequencies increased following butyrate treatment, we examined the level of IL-6 and TGF-β in rat plasma. Plasma levels of IL-6 in the colitis group were significantly higher than those in the control group, which was consistent with the results of the CD25 + Foxp3+ Treg analysis in rat peripheral blood cells (Fig. 3c). Nonetheless, there was no significant difference in TGF-β levels between the two groups (Fig. 3d). Butyrate treatment, however, resulted in significantly lower plasma levels of IL-6 (Fig. 3c) and significantly higher levels of TGF-β (Fig. 3d) when compared to the colitis group.

Th17 analysis of rats

IL-6 and TGF-β can stimulate native T cell differentiation into Th17 cells, which in turn produce and secrete IL-17
Fig. 3 Treg analysis in rats. The percentage of CD4⁺CD25⁺Foxp3⁺ Tregs (a). Quantified CD4⁺CD25⁺Foxp3⁺ Tregs (b). Plasma IL-6 (c). Plasma TGF-β (d). Data are the mean ± SE. n = 5–7. *P < 0.05; **P < 0.01

Fig. 4 Th17 analysis in rats. IL-17 immunohistochemical staining in the colon; upper and lower panel magnifications are × 40 and × 200, respectively. Scale bars, 200 μm (a). Quantified IL-17 immunohistochemical staining in colon (b). Immunoblotting for RORγt in mesenteric lymph nodes, shown are representative western blot results of three rats (c). Plasma IL-17 (d). Plasma IL-23 (e). n = 5–7. Data are the mean ± SE. n = 7. *P < 0.05; **P < 0.01
[2]. Th17 cells are identified by RORγt and IL-17, and IL-17 is detectable in both plasma and colon tissue in rats. IL-17 levels were found to be greater in the colitis group than in the control group, and decreased following butyrate treatment (Fig. 4a-b and d). Accordingly, butyrate treatment also decreased the colitis related RORγt increase in mesenteric lymph node (MLN) (Fig. 4c). IL-23 acts as an upstream regulator of Th17 cells and is critical for maintaining the stability and activation of Th17 cells [3]. Plasma IL-23 levels were increased in the colitis group, and likewise decreased following butyrate treatment (Fig. 4e).

Treg and Th17 cell differentiation in vitro
We performed in vitro Treg Th17 analysis using human PBMCs in order to verify the in vivo experiments. The in vitro studies demonstrated that the CD4+CD25+Foxp3+ subpopulation in the PBMCs was consistently up-regulated by butyrate treatment in a dose-dependent manner (Fig. 5a-b). IL-6 and TGF-β can stimulate native T cell differentiation into Th17 cells [2] and immature bone marrow dendritic cells (BMDCs) can be activated by lipopolysaccharide (LPS) from E.coli to secrete IL-23, which plays an important role in maintaining the stability and function of Th17 cells [21]. In vitro, IL-6 and TGF-β treatment significantly increased IL-17 and RORγt levels from rat splenocytes, especially in comparison to the non-stimulated control group (Fig. 6a). Moreover, IL-17 and RORγt levels were significantly lower in cells cultured with butyrate in a dose-dependent manner than in the PBS group (Fig. 6a). In vitro, UV-irradiated E.coli caused a significant increase in IL-23 secretion in the immature BMDCs in comparison to the non-stimulated control group (Fig. 6c). Additionally, IL-23 secretion was significantly lower in cells cultured with 80 μM butyrate than in the PBS group (Fig. 6c). UV-irradiated E.coli in the PBS group further caused a significantly increase in IL-17 and RORγt levels when splenocytes and BMDCs were co-cultured (Fig. 6b). UV-irradiated E. coli -treated cells incubated with 80 μM butyrate expressed significantly less IL-17 and RORγt levels (Fig. 6b).

Discussion
The major finding in this study was that butyrate exerted potent effects that ameliorated colitis lesions in a rat model by influencing Th cell differentiation and activation. This study proposes several possible mechanisms for these effects, including: 1) the inhibition of inflammatory Th17 cell activation and cytokine (IL-17) release, 2) the promotion of Treg cell differentiation and 3) alterations in the ratio in inflammatory cytokines (i.e., IL-10/IL-12) released by monocytes.

Firmicutes is a well-known butyrate-producing bacterium and several studies have confirmed that a reduction in F. prausnitzii and its product in IBD patients is inversely correlated with disease scores [22, 23]. Butyrate-producing microbiotic pharmabiotics have been shown to be effective in TNBS models and are destined for clinical trials [24]. Consistent with previous research in colitis models, our study confirmed that UC patients had...
lower fecal butyrate concentrations than did the control group. Our study utilized butyrate concentrations recommended by Di Sabatino et al. [25] and found that oral administration of butyrate resulted in increased percentage of butyric acid, fecal concentration of butyric acid, and total SCFA. This resulted in improved health status, including increased weight gain, lower colonic inflammation, and lower Neurath scores in the butyrate group rats as compared to the colitis group. These results were further confirmed by cytokine testing.

Th17 cells are a unique proinflammatory Th cell subset identified by RORγt and IL-17. Since the discovery of Th17, a number of studies have suggested that the IL-23/Th17/IL-17 pathway plays an important role in nearly all major autoimmune syndromes including IBD [3]. Studies have found that IL-17 levels are increased in both the colonic mucosa and serum of IBD patients, and IL-17 blocking therapy is being tested in patients with IBD [26, 27]. Serum concentration of total SCFAs in rodents is around 0.1 ~ 1 mM, among which only 10% are butyrate [28, 29]. Therefore, the serum concentration of butyrate is estimated to be approximately 100 μM at most. Under physiological concentration of butyrate, we found that the high levels of RORγt and IL-17 caused by TNBS were both significantly reduced by butyrate treatment, suggesting their protective nature in the onset of colitis. IL-6 signaling is required for Th17 cell lineage commitment and its differentiation is enforced by TGF-β [2]. IL-23 is an essential upstream regulator of Th17 cells that maintains Th17 activity and function, and immature bone marrow dendritic cells (BMDCs) can be activated by lipopolysaccharide (LPS) from E.coli to secrete IL-23 [3, 21]. Our study found that plasma levels of IL-23 and IL-6 were significantly increased by TNBS treatment.

Fig. 6 Th17 cell differentiation in vitro. IL-17 release from rat splenocytes (left) and immunoblotting for RORγt in rat splenocytes (right) in vitro (a). IL-17 release from co-cultured BMDCs and splenocytes (left) and immunoblotting for RORγt in co-cultured BMDCs and splenocytes (right) in vitro (b). IL-23 released from BMDCs with UV-irradiated E. coli stimulation (c). Data are the mean ± SE. n = 4. *P < 0.05; **P < 0.01. But40, 40 μM sodium butyrate. But80, 80 μM sodium butyrate.
and reduced by butyrate administration. This suggests that the IL-23/Th17/IL-17 pathway is an effective target for butyrate treatment in the setting of inflammatory colitis. Our in vitro experiments in rat splenocytes and BMDCs further confirmed this in vivo data. When splenocytes differentiated into Th17 cells in vitro, we demonstrated a similar cytokine release profile to that observed in colitis rats. Only a high dose of butyrate (80 μM) could suppress the secretion of IL-23 by BMDCs and the secretion of IL-17 by the splenocytes when co-cultured with BMDCs. Consistent with IL-17 levels from cultured splenocytes, RORγt levels in splenocytes also decreased following butyrate treatment. Taken together, this suggests that butyrate inhibits Th17 differentiation.

Regulatory T cells (Treg) also differentiate from Th cells in presence of TGF-β [4]. Tregs maintain homeostasis by producing anti-inflammatory cytokines such as IL-10 and exert important negative regulation of Th17 cells. Impaired function of IL-10 and the IL-10 receptor are associated with aggressive IBD [6]. The insufficiency of Tregs in germ-free mice can be restored via a high-fiber diet induced by butyrate in vivo. This is corroborated by in vitro studies demonstrating that microbes producing butyrate stimulate the differentiation of Tregs and exert anti-inflammatory activity in the intestinal mucosa of a mouse model [30, 31]. Consistent with previous results, our in vivo study demonstrated butyrate treatment increased both the percentage of Treg and the levels of IL-10, suggesting that the protective effect of butyrate on intestinal inflammation was correlated with the level of IL-10. TGF-β, together with IL-6, can stimulate native T cells to differentiate into Th17 cells [2]. Yet without sufficient IL-6, TGF-β stimulates native T cells differentiation into Tregs [20]. Increased levels of Tregs in rat peripheral blood cells were found in combination with increased plasma levels of TGF-β, whereas butyrate treatment decreased IL-6 levels. The in vitro experiments in human PBMCs further confirmed this in vivo data. A high dosage of butyrate (80 μM) could promote secretion of TGF-β by PBMCs and increased Treg frequencies in PBMCs.

Conclusions
In summary, a fine balance exists between Treg and Th17 cells in a healthy state. The same Th cell pool that generates Treg is also capable of producing Th17 cells, and this is coordinated by cytokines including IL-10, TGF-β and IL-6. Our results suggest that butyrate, a well-known metabolite, played a key role in regulating this Treg/Th17 balance and in turn yielded important insights for the treatment of IBD.

Abbreviations
BMDC, bone marrow DC cells; CD, cרובn disease; IBD, inflammatory bowel disease; IL, interleukin-23; LPS, lipopolysaccharide; PBMC, peripheral blood mononuclear cell; RORγt, retinoic orphan receptor γt; SCFA, short chain fatty acid; TGF-β, transforming growth factor β; Th17, helper T lymphocyte 17; TNBS, 2,4,6-trinitrobenzenesulfonic acid; UC, ulcerative colitis

Acknowledgements
The authors thank the advice provided by Ms Hongjing Yu and Mr. Lichuan Guo. We thank Professor Liu for the technical assistance.

Funding
This study has been supported by a research grant from Beijing Renze Foundation (ZX-IBD-13002), the National Natural Science Foundation of China (No. 81170359), Nanjing Foundation for Development of Science and Technology (No.YK15232) and the Outstanding Youth Project of Nanjing City (No.JQX14005).

Availability of data and materials
Clinical data will not be made available in order to protect the participants’ identity.

Authors’ contributions
MZ designed the study; MZ and OZ did the cell and mice experiments; XH and HZ collected fecal and tissue samples; HZ, TF and MZ performed the FACS and IHC analysis; MZ, XH and HZ drafted the manuscript and performed the rest ELISA experiment; RGD did the language editing; JZ and CY supervised and supported the study. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
All experiments utilizing animal and human samples were approved by the Ethical Committee of Medical Research, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School. Both patients and healthy participants were consented and signed the agreement to participate in our study.

Author details
1Department of Gastroenterology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing University, Nanjing, China. 2Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, China. 3School of Life Sciences, Fudan University, Shanghai, China. 4Institutes of Biomedical Sciences, Fudan University, Shanghai, China. 5Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 6Department of Gastroenterology, Nanjing Jiangbei People’s Hospital Affiliated to Southeast University Medical School, Nanjing, China. 7State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, China.

Received: 4 January 2016 Accepted: 21 July 2016
Published online: 30 July 2016

References
1. Dalal SR, Chang EB. The microbial basis of inflammatory bowel diseases. J Clin Invest. 2014;124(10):4190–6.
2. Mangar PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the Th(17) lineage. Nature. 2006;441(7090):231–4.
3. Yang JF, Sundrud MS, Skepnjer J, Yamagata T. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol Sci. 2014;35(10):493–500.
4. Gibson DJ, Ryan EJ, Doherty GA. Keeping the Bowel Regular: The Emerging Role of Treg as a Therapeutic Target in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2013;19(12):2716–24.
5. Zheng Y, Rudensky AY. Foxp3 in control of the regulatory T cell lineage. Nat Immunol. 2007;8(5):457–62.
6. Gloeker EO, Kotlarz D, Boztug K, Gertz EM, Schaffer AA, Noyan F, Perro M, Dixtellhorst J, Alrough A, Murugan D, et al. Inflammatory Bowel Disease and...
7. Fantini MC, Rio A, Fina D, Caruso R, Sara M, Stolfi C, Becker C, Macdonald TT, Pallone F, Neurath MF, et al. Smad7 Controls Resistance of Colitogenic Cells to Regulatory T Cell-Mediated Suppression. Gastroenterology. 2009;136(4):1308–16.
8. Bettelli E, Carrier YJ, Gao WD, Kom T, Strom TB, Okkula M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells. Nature. 2006;441(7090):235–8.
9. Astbury SM, Corfe BM. Uptake and metabolism of the short-chain fatty acid butyric acid, a critical review of the literature. Curr Drug Metab. 2012;13(6):815–21.
10. Berni Canani R, Di Costanzo M, Leone L. The epigenetic effects of butyrate: potential therapeutic implications for clinical practice. Clin Epigenetics. 2012;4(1):4.
11. Hallet C, Bjork C, Nyman M, Poussete A, Ganni C, Svensson H. Increasing fecal butyrate in ulcerative colitis patients by diet. Controlled pilot study. Inflamm Bowel Dis. 2003;9(2):116–21.
12. Bennebroek Evertsz F, Nieuwkerk PT, Stokkers PC, Ponsioen CY, Bockting CL, Sturker J, Brouwers W, Veldink JH, Wijngaard JN. Beneficial effects of butyric acid on cytokine production in ulcerative colitis. J Gastrointest Med. 2001;25(5):213–9.
13. Foligne B, Nutten S, Steidler L, Dennin V, Goudercourt D, Mercenier A, Pot B. Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria. Technical and methodological aspects. Digest Dis Sci. 2006;51(2):390–400.
14. Neurath MF, Fuss I, Kessal Bi, Stuber E, Strober W. Antibodies to Interleukin-12 defines dysbiosis in patients with ulcerative colitis. J Crohns Colitis. 2013;7(11):890–900.
15. Brown RS, Wahl RL. Overexpression of Glut-1 Glucose-Transporter in Human Breast-Cancer - an Immunohistochemical Study. Cancer. 1993;72(10):2979–85.
16. Fantini MC, Rio A, Fina D, Caruso R, Sara M, Stolfi C, Becker C, Macdonald TT, Pallone F, Neurath MF, et al. Smad7 Controls Resistance of Colitogenic Cells to Regulatory T Cell-Mediated Suppression. Gastroenterology. 2009;136(4):1308–16.
17. Steinman RM. Generation of Large Numbers of Dendritic Cells from Mouse Bone-Marrow Cultures Supplemented with Granulocyte Macrophage Colony-Stimulating Factor. J Exp Med. 1992;176(6):1693–702.
18. Sokol H, Pignolet B, Assenmacher ME, Gratadoux JJ, Blugone S, Bridonneau C, Furet JP, Corthier G, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium that defines dysbiosis in patients with ulcerative colitis. Gut. 2007;56(3):436–43.
19. Tanabe S, Kinuta Y, Saito Y. Bifidobacterium infantis suppresses proinflammatory interleukin-17 production in murine splenocytes and dextran sodium sulfate-induced intestinal inflammation. Int J Mol Med. 2008;22(2):181–5.
20. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikeha S, Muramatsu S, Steinman RM. Generation of Large Numbers of Dendritic Cells from Mouse Bone-Marrow Cultures Supplemented with Granulocyte Macrophage Colony-Stimulating Factor. J Exp Med. 1992;176(6):1693–702.
21. Schleissner U, Chopra M, Bellhac K, Appelt C, Vogel S, Schumann J, Panov L, Vogt K, Schlicker S, Olek S, et al. Generation of highly effective and stable murine alloreactive Treg cells by combined anti-CD4 mAb, TGF-beta, and RA treatment. Eur J Immunol. 2013;43(12):3291–305.
22. Loos M, Remaut E, Rottier P, De Creus A. Genetically Engineered Lactococcus lactis Secreting Murine IL-10 Modulates the Functions of Bone Marrow-Derived Dendritic Cells in the Presence of LPS. Scand J Immunol. 2009;69(2):130–9.
23. Cao Y, Shen J, Fan ZH. Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature. Gastroent Res Pract. 2014.
24. Machiels K, Joossens M, Sabatino A, Moreira R, Ciccocioppo R, Cazzola P, Gotti S, Tinozzi FP, Tinozzi S, Corazza GR. Oral butyrate for mildly to moderately active Crohn's disease. Aliment Pharm Ther. 2005;22(9):789–94.
25. Zhang M, Qi X, Zhang H, Yang X, Hong N, Yang Y, Chen H, Yu C. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PLoS One. 2014;9(10), e109146.